Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma

Background Tebentafusp, a bispecific (gp100×CD3) ImmTAC, significantly improved overall survival (OS) outcomes for HLA-A*02:01+ adult patients with untreated metastatic uveal melanoma (mUM) and showed promising survival in previously treated mUM with 1-year OS of 62% in the primary analysis of study...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jessica C Hassel, Alexander N Shoushtari, Omid Hamid, Takami Sato, Paul Nathan, Marcus O Butler, Jason J Luke, Richard D Carvajal, Leonel Hernandez-Aya, Douglas B Johnson, Laura Collins, Enrique Espinosa, Joseph J Sacco, Serge Leyvraz, Alexandra Ikeguchi, Matthew Rioth, Chris Holland, Josep M Piulats
Format:	Artigo
Idioma:	Inglês
Publicat:	BMJ Publishing Group 2024-06-01
Col·lecció:	Journal for ImmunoTherapy of Cancer
Accés en línia:	https://jitc.bmj.com/content/12/6/e009028.full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!